TSHA - Taysha Gene Therapies, Inc.
IEX Last Trade
1.75
0 0%
Share volume: 32,969
Last Updated: Fri 27 Dec 2024 08:30:09 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$1.75
0.00
0.00%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-11 | 2022-11-08 | 2023-03-28 | 2023-05-11 | 2023-08-14 | 2023-11-14 | 2024-03-19 | 2024-05-14 | |
| Assets | |||||||||
| Total Assets | 142.332 M | 111.468 M | 126.276 M | 101.600 M | 81.543 M | 195.769 M | 172.731 M | 152.999 M | |
| Current Assets | 76.835 M | 43.002 M | 96.417 M | 72.358 M | 54.115 M | 171.807 M | 149.868 M | 130.597 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 10.596 M | 8.696 M | 8.537 M | 8.933 M | 9.032 M | 5.529 M | 3.479 M | 4.168 M | |
| Short Term Investments | 10.596 M | 8.696 M | 8.537 M | 8.933 M | 9.032 M | 5.529 M | 3.479 M | 4.168 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 66.239 M | 34.306 M | 87.880 M | 63.425 M | 45.083 M | 164.278 M | 143.940 M | 123.980 M | |
| Total Non-current Assets | 65.497 M | 68.466 M | 29.859 M | 29.242 M | 27.428 M | 23.962 M | 22.863 M | 22.402 M | |
| Property Plant Equipment | 61.011 M | 63.954 M | 14.963 M | 14.642 M | 14.139 M | 11.169 M | 10.826 M | 10.686 M | |
| Other Assets | 1.849 M | 1.875 M | 12.259 M | 11.963 M | 10.652 M | 10.156 M | 9.886 M | 9.565 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 142.332 M | 111.468 M | 126.276 M | 101.600 M | 81.543 M | 195.769 M | 172.731 M | 152.999 M | |
| Total liabilities | 109.622 M | 100.342 M | 125.327 M | 116.548 M | 118.657 M | 244.883 M | 97.794 M | 99.150 M | |
| Total current liabilities | 42.953 M | 33.139 M | 62.790 M | 54.455 M | 50.641 M | 180.451 M | 36.756 M | 38.637 M | |
| Accounts Payable | 23.967 M | 15.251 M | 10.946 M | 9.002 M | 10.766 M | 7.520 M | 6.366 M | 10.380 M | |
| Other liabilities | 3.480 M | 3.934 M | 4.130 M | 4.004 M | 10.134 M | 6.783 M | 1.577 M | 1.502 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 63.189 M | 63.269 M | 58.407 M | 58.089 M | 57.882 M | 57.649 M | 59.461 M | 59.011 M | |
| Other liabilities | 3.480 M | 3.934 M | 4.130 M | 4.004 M | 10.134 M | 6.783 M | 1.577 M | 1.502 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 32.710 M | 11.126 M | 949.000 K | -14.948 M | -37.114 M | -49.114 M | 74.937 M | 53.849 M | |
| Common stock | 40.142 M | 40.938 M | 56.553 M | 63.261 M | 64.245 M | 125.701 M | 211.280 M | 231.249 M | |
| Retained earnings | -319.633 M | -345.940 M | -401.441 M | -419.063 M | -443.661 M | -560.748 M | -513.007 M | -537.068 M |